Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Mega Genomics Limited ( (HK:6667) ).
Mega Genomics Limited has announced a delay in the publication of its 2025 Interim Report due to pending issues related to its 2024 Annual Results and Report. Despite the suspension of trading, the company continues its business operations and is actively working on fulfilling resumption guidance from the Stock Exchange. An independent investigation and an internal control review are underway to address any potential deficiencies and ensure compliance, with updates to be provided to shareholders and investors as necessary.
More about Mega Genomics Limited
Mega Genomics Limited is a leading genetic testing platform company in China, primarily offering consumer genetic testing services and cancer screening services. The company has collaborated with healthcare institutions in over 340 cities across China and has conducted over 24 million genetic tests.
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.61B
See more data about 6667 stock on TipRanks’ Stock Analysis page.